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1. INTRODUCTION
The efficiency of crossover trials often makes them the best design for a clinical trial. Administering
multiple treatments to patients reduces the standard error of the estimated treatment effects compared
to a parallel trial design with an equal number of patients. Therefore, whilst restrictions to their use
exist; such as a requirement for patients to begin each new treatment period in a comparable state to
those completed, crossover trials are the design of choice in many settings (Jones and Kenward, 2014;
Senn, 2002), resulting in them accounting for 22% of all published trials in December 2000 for example
(Mills et al., 2009).
In a parallel design setting, group sequential methods are frequently utilized to improve a clinical
trials efficiency (Jennison and Turnbull, 2000). These designs incorporate interim analyses which allow
for early rejection of null hypotheses; efficacy stopping, or early stopping for lack of benefit; futility
stopping. This way, the expected sample size required can be reduced over the more classical single-stage
approach. Moreover, multi-arm multi-stage designs, which allow multiple experimental treatments to
share a control group, can increase efficiency even further (Parmar et al., 2014).
Group sequential methods are not frequently used in crossover trial settings however, in particular
ones with multiple experimental treatments. Hauck et al. (1997) investigated the performance of group
sequential trials for average bioequivalence employing an AB/BA crossover design, whilst Jennison and
Turnbull (2000) provided one possible analysis method for a group sequential AB/BA crossover with a
normally distributed endpoint. No one, to the best of our knowledge, has explored group sequential theory
for crossover trials with more than one experimental treatment being compared to a shared control.
Thus, one possible explanation for the lack of group sequential crossover trials may be that there
is not yet available a formal proof of how to strongly control the familywise error rate of such a trial
with multiple experimental treatments; since such a proof is usually required for regulatory approval
(Wason et al., 2014). In comparison to a proof for a parallel multi-arm multi-stage design (Magirr et al.,
2012), proving strong control of the familywise error rate is complicated here due to difficulties associated
with the covariance structure implied by mixed model analysis. As has been remarked, multiple testing
corrections for mixed models are only presently available for certain specific circumstances (Bender and
Lange, 2001). Extension to this setting is particularly significant though given the noted advantages of
comparing multiple experimental treatments to a shared control, both in terms of trial management and
sample size (Parmar et al., 2014).
Potential exists, given a proof, for the efficiency of crossover trial designs to be improved. In this work,
we begin by providing such a proof for a linear mixed model using period and treatment as fixed effects,
and individuals as random effects. Following this, using the four treatment, four-period TOMADO trial
(Quinnell et al., 2014) as an example, we explore and discuss the efficiency gains that group sequential
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designs could bring in a crossover setting.
2. METHODS
2.1. Notation, Hypotheses and Analysis
The trial is assumed to have D ≥ 2 treatments initially, indexed d = 0, . . . , D − 1. Treatments d =
1, . . . , D − 1 are experimental, to be compared to the control d = 0. A maximum of L stages are
planned for the trial. At each stage patients are allocated to each of a set of treatment sequences, which
specify an order in which a patient receives treatments. The sequences used at each stage are determined
by the number of treatments remaining in the trial at that stage. Without loss of generality, we will
assume that if a treatment, or treatments, are dropped, it is treatment D − 1 dropped first, then D − 2,
and so on, since treatments can always be re-labelled at each interim analysis. Then, we denote by
Sr = {sri : i = 1, . . . , |Sr|}, r = 2, . . . , D, the set of sequences for patient treatment allocation when
r treatments remain in the trial, with each Sr written in the form assuming it is exactly treatments
d = 0, . . . , r − 1 that remain. We further constrain each Sr to contain only complete block sequences
that are balanced for period. Specifically, complete block allocation requires all sequences to contain each
treatment remaining in the trial exactly once, and period balance requires an equal number of patients
to receive each treatment remaining in the trial in each period. These constraints allow the use of the
popular Latin and Williams squares (Jones and Kenward, 2014).
A fixed group size n is used for each stage of the trial, and is chosen such that at every stage each
sequence is used an equal number of times. Thus n must be divisible by the lowest common multiple of
|S2| , . . . , |SD|. Designing the trial in this manner ensures each treatment is considered equally.
Outcome data is assumed to be normally distributed, and a linear mixed model is used for analysis,
given by
yijkl = µ0 + pij + τd[j,k,l] + sikl + ijkl,
or
Y = Xβ +Zb+ ,
where
• Y is the vector of responses, containing the values of the yijkl; the response for individual i, in
period j, on sequence k, in stage l,
• β is the vector of fixed effects, of length 2D − 1, consisting of
– µ0 the mean response on treatment 0 in period 1, an intercept term,
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– pij the fixed period effect for period j, with the identifiability constraint pi1 = 0. Note that
period is reset to 1 for each new stage of the trial. That is, the first period of stage 2 is treated
as period 1 rather than period D + 1, and similarly for later stages. Thus, we have exactly
D − 1 non-zero period effects given our restriction to complete block sequences.
– τd[j,k,l] is the fixed direct treatment effect for an individual in period j, on sequence k, in stage
l, with the identifiability constraint τ0 = 0,
• X is the matrix linking the fixed effects to the vector of responses,
• b is the vector of random effects, consisting of the sikl; the random effect for individual i, on
sequence k, in stage l,
• Z is the matrix linking the random effects to the vector of responses,
•  is the vector of residuals, consisting of the ijkl; the residual for individual i, in period j, on
sequence k, in stage l.
Additionally, denoting by σ2b > 0 and σ
2
e > 0 the between and within subject variances respectively, we
take
cov(si1k1l1 , si2k2l2) = σ
2
bδi1i2δk1k2δl1l2 ,
cov(i1j1k1l1 , i2j2k2l2) = σ
2
eδi1i2δj1j2δk1k2δl1l2 ,
where δij is the Kronecker Delta function. Incorporation of fixed effects for period and treatment only,
and our chosen covariance structure above, are the conventional choices for a crossover trial (Jones and
Kenward, 2014).
We test D − 1 hypotheses. Since we are interested in testing the efficacy of experimental treatments
in comparison to a control, we consider the case of one-sided alternative hypotheses H0d : τd ≤ 0, H1d :
τd > 0, for d = 1, . . . , D − 1.
At each interim analysis the above model is used to compute an estimate, βˆl (l = 1, . . . , L), for β
through the standard maximum likelihood estimator of a linear mixed model
βˆl = (X
TΣ−1X)−1XTΣ−1Y ∼MVN {β, (XTΣ−1X)−1} ,
where Σ = Zcov(b, b)ZT + cov(, ) (Fitzmaurice et al., 2011). From this we acquire τˆ l =
(τˆ1l, . . . , τˆD−1l)T, which consists of the maximum likelihood estimates for each τd. Then, each τˆdl is
standardized to give D − 1 test statistics Zdl = τˆdlI1/2dl , d = 1, . . . , D − 1, with Idl = {var(τˆdl)}−1 the
information level for treatment d at interim analysis l. Since τˆ l is estimated via a normal linear model
we know that E(Zdl) = τdI
1/2
dl (Jennison and Turnbull, 2000).
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Given fixed futility boundaries, fdl, and efficacy bounds, edl, the following stopping rules are used at
each analysis l = 1, ..., L, for each experimental treatment d = 1, . . . , D − 1 satisfying fdm ≤ Zdm < edm
for m = 1, . . . , l − 1
• if Zdl < fdl treatment d is dropped without rejecting H0d,
• if fdl ≤ Zdl < edl the trial is continued with treatment d still present,
• and if edl ≤ Zdl treatment d is dropped and H0d rejected.
The control treatment, d = 0, remains present at every undertaken stage, and we only proceed to an
additional stage if there is at least one experimental treatment remaining in the trial. It is convenient to
take fdl = fl and edl = el for all d and l, as well as fL = eL in order to ensure the trial conforms to the
desired maximum number of stages and so that a conclusion is made for each H0d. Note that rejection
of one treatment’s null hypothesis does not end the trial. Furthermore, with this formulation, once a
treatment is dropped from the trial its standardised treatment effect is not tested at any future analyses.
In what follows, we will make use of the vectors ωR = (ωR1, . . . , ωRD−1)T and ψR =
(ψR1, . . . , ψRD−1)T. Here, ωRd ∈ {1, . . . , L} is the analysis at which experimental treatment d was
dropped from the trial. Moreover, ψRd ∈ {0, 1}; with ψRd = 1 if experimental treatment d was dropped
for efficacy, and is 0 otherwise. Prior to a trials commencement ωR andψR are unknown random variables.
However, the probability that the trial progresses according to some particular ω = (ω1, . . . , ωD−1)T and
ψ = (ψ1, . . . , ψD−1)T, given a vector of true response rates τ = (τ1, . . . , τD−1)T, can be computed us-
ing multivariate normal integration. More specifically, given this particular (ω,ψ) pair the covariance
between, and the information level of, the test statistics can be computed and the following integral
evaluated (see Jennison and Turnbull (2000) or Wason (2015) for further details)
pr(ωR = ω,ψR = ψ | τ ) =
∫ u(1,ω1,ψ1)
l(1,ω1,ψ1)
. . .
· · ·
∫ u(L,ωD−1,ψD−1)
l(L,ωD−1,ψD−1)
φ
{
x, r(τ , L) ◦ I1/2(ω,ψ),Λ(ω,ψ)
}
dxL(D−1) . . .dx11,
where
• x = (x11, . . . , x1(D−1), . . . , xL1, . . . , xL(D−1))T,
• φ{x,µ,Λ} is the probability density function of a multivariate normal distribution with mean µ
and covariance matrix Λ, evaluated at vector x,
• r(τ , L) is the vector formed by repeating τ L times,
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• I(ω,ψ) =
(
IT1,(ω,ψ), . . . , I
T
L,(ω,ψ)
)T
, where I l,(ω,ψ) = (I1l, . . . , I(D−1)l)T(ω,ψ) is the vector of informa-
tion levels for the estimated treatment effects at interim analysis l, according to (conditional on)
the particular (ω,ψ) being considered,
• ◦ denotes the Hadamard product of two vectors,
• the square root of the vector I(ω,ψ) is taken in an element wise manner,
• l and u are functions that tell us the lower and upper integration limits for the test statistic Zdl
given values for l, ωd and ψd. For example, l(1, 2, 1) = f1 and u(1, 2, 1) = e1, whilst l(2, 2, 1) = e2
and u(2, 2, 1) =∞, and then l(l, 2, 1) = −∞ and u(l, 2, 1) =∞ for l > 2,
• Λ(ω,ψ) is the covariance matrix between the standardized test statistics at and across each interim
analysis according to (ω,ψ). Thus, using Zl = (Z1l, . . . , ZD−1l)T, we have
Λ(ω,ψ) =

cov (Z1,Z1 | ω,ψ) . . . cov (Z1,ZL | ω,ψ)
...
. . .
...
cov (ZL,Z1 | ω,ψ) . . . cov (ZL,ZL | ω,ψ)
 .
However, Zl = τˆ l ◦ I1/2l,(ω,ψ), and by the properties of normal linear models cov(τˆ l1 , τˆ l2 | ω,ψ) =
cov(τˆ l2 , τˆ l2 | ω,ψ) (l1, l2 = 1, . . . , L; l1 ≤ l2) (Jennison and Turnbull, 2000), giving
cov(Zl1 ,Zl2 | ω,ψ) = diag(I1/2l1,(ω,ψ))cov(τˆ l2 , τˆ l2 | ω,ψ)diag(I
1/2
l2,(ω,ψ)
), (2.1)
for l1, l2 = 1, . . . , L, l1 ≤ l2, and where diag(v) is the matrix formed by placing the elements of
vector v along the leading diagonal.
Note that Equation (2.1) in conjunction with the expectations of our standardised test statistics, and the
observation that (ZT1 , . . . ,Z
T
L)
T is multivariate normal, can be restated simply as that our test statistics
follow the canonical joint distribution (Jennison and Turnbull, 2000).
2.2. Familywise Error Rate Control
It is a common requirement of clinical trial designs that the probability of one or more false rejections
within the family of null hypotheses is not greater than some α. This is known as strong control of the
familywise error rate. In this section we establish strong control for our considered trial design.
To evaluate the familywise error rate of a design, for any τ , the above integral can be evaluated for all
ω and ψ that would imply a type-I error is made, and the results summed. In order to demonstrate how
to strongly control though, it is essential to know the forms of the I l,(ω,ψ) and Λ(ω,ψ) for each (ω,ψ).
However, by Equation (2.1), the I l,(ω,ψ) and Λ(ω,ψ) can be determined if cov(βˆl, βˆl | ω,ψ) is known for
l = 1, . . . , L.
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Thus, consider the matrix cov(βˆl, βˆl | ω,ψ) for some l ≤ L and any (ω,ψ). We compute values
for Llr (r = 1, . . . , D); the number of stages of the trial, up to analysis l, in which r treatments were
remaining. Since we do not continue the trial unless at least one experimental treatment remains, Ll1 = 0
always. It will be convenient however to still include this value. Moreover, it is clear that the Llr are
uniquely determined given (ω,ψ). Now, cov(βˆl, βˆl | ω,ψ) can always be decomposed to be a sum over
the determined Llr and the pre-specified sequences Sr (see Fitzmaurice et al. (2011) for details)
cov(βˆl, βˆl | ω,ψ) = cov(βˆl, βˆl | Ll1, . . . , LlD),
=
 D∑
r=1
Llr
n
|Sr|
|Sr|∑
i=1
XTsriΣ
−1
r Xsri
−1 .
Here Xsri is the uniquely defined r × (2D − 1) design matrix for a single patient allocated to sequence
sri, and Σr is the easily computed r× r covariance matrix of the responses for a single patient allocated
r treatments in total. The factor n/ |Sr| arises from the number of patients allocated to each sequence
sri by our choice of period balance.
We now establish two key results about cov(βˆl, βˆl | Ll1, . . . , LlD). Following this, we provide a proof
detailing how to strongly control the familywise error rate.
Theorem 2.1. Let β = (µ0, pi2, . . . , piD, τ1, . . . , τD−1)T. Consider an analysis to be performed after some
number of stages l. Then
1. We have
cov(βˆl, βˆl | Ll1, . . . , LlD−1 = 0, LlD = l) =
 ln
|SD|
|SD|∑
i=1
XTsDiΣ
−1
D XsDi
−1 ,
=
1
ln

F GT GT
G H 0D−1,D−1
G 0D−1,D−1 H
 , (2.2)
where
F = σ2b +
2D − 1
D
σ2e ,
Gpq = −σ2e (p = 1, . . . , D − 1; q = 1),
Hpq = σ
2
e(1 + δpq) (p = 1, . . . , D − 1; q = 1, . . . , D − 1).
2. If q ≥ 2 is the largest integer such that Llr = 0 for r = 1, . . . , q − 1, then the covariance of the
estimates of the fixed effects pˆi2l, . . . , pˆiql, τˆ1l, . . . , τˆq−1l is identical to that it would be for Ll1 =
· · · = LlD−1 = 0. Moreover, the covariance between the estimates of pˆi2l, . . . , pˆiql, τˆ1l, . . . , τˆq−1l and
the estimates of pˆiq+1l, . . . , pˆiDl, τˆql, . . . , τˆD−1l is also identical to that it would be for Ll1 = · · · =
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LlD−1 = 0.
Proof. See Appendix C.
Note that part (1) of the above theorem implies
cov(τˆd1l, τˆd2l | Ll1 = · · · = LlD−1 = 0, LlD = l) =
σ2e
ln
(1 + δd1d2),
for d1, d2 ∈ {1, . . . , D − 1}. This is the familiar result for complete block sequences that there is no
dependence upon the between patient variance σ2b (Jones and Kenward, 2014).
Theorem 2.2. A group sequential crossover trial of the type considered, with D ≥ 2, testing the D − 1
hypotheses H0d : τd ≤ 0, H1d : τd > 0, attains a maximal value of its familywise error rate for τ1 = · · · =
τD−1 = 0.
Proof. Theorem 2.1 implies that elements of the covariance matrix cov(τˆ l, τˆ l) that differ from the case
where no treatments have been dropped are exactly those corresponding to unstandardized test statistics
no longer of importance. Consequently, the values of I l,(ω,ψ) and Λ(ω,ψ) that differ from the case
ω = (L, . . . , L)T are only ever those corresponding to limits of integration given by (−∞,∞) in our
computation of pr(ωR = ω,ψR = ψ | τ ). By the marginal distribution properties of the multivariate
normal distribution, we therefore need only consider one matrix Λ(ω,ψ), and one set of vectors I l,(ω,ψ)
(l = 1, . . . , L); exactly those given by the case ω = (L, . . . , L)T. Denote these by Λ and I l, and set
I = (IT1 , . . . , I
T
L)
T. For more information on this, see Appendix A. We now have
pr(ωR = ω,ψR = ψ | τ ) =
∫ u(1,ω1,ψ1)
l(1,ω1,ψ1)
. . .
· · ·
∫ u(L,ωD−1,ψD−1)
l(L,ωD−1,ψD−1)
φ
{
x, r(τ , L) ◦ I1/2,Λ
}
dxL(D−1) . . .dx11.
Now, consider without loss of generality the probability we reject H01, and denote by Ω and Ψ the sets of
all possible ω andψ respectively. By integrating over all possible values of ω2, . . . , ωD−1 and ψ2, . . . , ψD−1,
we have that the probability we reject each H01 does not depend on the values of τ2, . . . , τD−1, i.e. on
the other treatments tested
pr (Reject H01 | τ ) =
∑
{ψ∈Ψ:ψ1=1}
∑
ω∈Ω
pr(ωR = ω,ψR = ψ | τ ),
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=
∑
{ψ∈Ψ:ψ1=1}
∑
ω∈Ω
∫ u(1,ω1,ψ1)
l(1,ω1,ψ1)
. . .
· · ·
∫ u(L,ωD−1,ψD−1)
l(L,ωD−1,ψD−1)
φ
{
x, r(τ , L) ◦ I1/2,Λ
}
dxL(D−1) . . .dx11,
=
L∑
ω1=1
∫ u(1,ω1,1)
l(1,ω1,1)
. . .
· · ·
∫ u(L,ω1,1)
l(L,ω1,1)
φ
{
(x11, . . . , xL1)
T, r(τ1, L) ◦ I1/2τ1 ,Λτ1
}
dxL1 . . .dx11,
where Iτ1 and Λτ1 are the restrictions of I and Λ to rows and columns corresponding to experimental
treatment d = 1 respectively. This final form for pr (Reject H01 | τ ) is identical to that it would be in the
case D = 2. Therefore to ascertain the τ giving the maximal familywise error rate of a trial with D ≥ 2,
it suffices to consider which τ∗ ≤ 0 maximises the probability H01 is rejected in a trial with D = 2 initial
treatments. For then, τ = (τ∗, . . . , τ∗)T using this τ∗, will provide the maximum probability of rejecting
at least one true H0d for some d, i.e. the maximum familywise error rate. To see this, consider the
familywise error rate for τ = (τ∗, . . . , τ∗)T. If one changes some individual element τd1 of this vector, this
does not effect the probability that H0d2 is rejected for d2 6= d1, and it can only decrease the probability
that H0d1 is incorrectly rejected. Thus overall, straying from this τ = (τ∗, . . . , τ∗)
T can only decrease the
familywise error rate.
Thus, now consider all possible realisations of the test statistics of a trial with D = 2, and their
associated values of (ω,ψ) = (ω1, ψ1). We have Z = (Z11, . . . , Z1L)
T ∈ RL, with Z1L = · · · = Z1ω1 if
the trial was stopped at stage ω1. Now consider increasing the value of the test statistics by some η > 0.
All instances before where H01 was rejected will still exceed the efficacy bound of that stage, or earlier,
and so H01 will still be rejected. Therefore, the probability of rejecting H01 is at least as large as before.
Thus, increasing the value of τ1 ≤ 0 causes a non-decreasing change in the value of the type-I error rate.
Therefore, the probability of rejecting H01 is maximized by τ1 = 0; implying in turn that the maximal
familywise error rate of a trial with D ≥ 2 is given by τ = (τ1, . . . , τD−1)T = (0, . . . , 0)T.
2.3. Design Characteristics
A trial will now be fully specified given values for D, L, σ2e and n, as well as choices for the Sr, and
the futility and efficacy boundaries, f1, . . . , fL and e1, . . . , eL respectively. Given these, Λ and I can be
computed using the results above. Then, by Theorem 2.2 we can strongly control the familywise error
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rate to α for this design using the following sum of integrals
α =
∑
{ψ∈Ψ:Σdψd>0}
∑
ω∈Ω
∫ u(1,ω1,ψ1)
l(1,ω1,ψ1)
. . .
· · ·
∫ u(L,ωD−1,ψD−1)
l(L,ωD−1,ψD−1)
φ {x, r(0, L(D − 1)),Λ} dxL(D−1) . . . dx11,
Additionally, suppose that we wish to power this trial to reject a particular null hypothesis, without loss
of generality H01, at some clinically relevant difference τ1 = δ. The type-II error rate β for H11 is then
given by
β = 1−
L∑
ω1=1
∫ u(1,ω1,1)
l(1,ω1,1)
. . .
· · ·
∫ u(L,ω1,1)
l(L,ω1,1)
φ
{
(x11, . . . , xL1)
T, r(δ, L) ◦ I1/2τ1 ,Λτ1
}
dxL1 . . . dx11.
Moreover, denoting by N and O the total number of patients and observations required by the trial
respectively, we can compute the expected sample size, E(N | τ ), or expected number of observations,
E(O | τ ), for any τ , according to
E(N | τ ) =
∑
ψ∈Ψ
∑
ω∈Ω
pr(ωR = ω,ψR = ψ | τ )N(ω,ψ),
E(O | τ ) =
∑
ψ∈Ψ
∑
ω∈Ω
pr(ωR = ω,ψR = ψ | τ )O(ω,ψ).
Here, N(ω,ψ) and O(ω,ψ) are functions that give the number of patients and observations respectively,
required by a trial that progresses according to (ω,ψ). Specifically
N(ω,ψ) = n max
{d=1,...,D−1}
ωd,
O(ω,ψ) = n
L∑
l=1
(
D−1∑
d=1
I{ωd≥l} + 1
)
,
where I{ωd≥l} = 1 if ωd ≥ l, and is 0 otherwise.
3. EXAMPLE: TOMADO
As an example of how to design a group sequential crossover trial with strong control of the familywise
error rate, we will make use of the TOMADO crossover randomized controlled trial (Quinnell et al.,
2014). This open-label trial compared three experimental treatments to a single control for the treatment
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of sleep apnoea-hypopnoea using a four-treatment four-period crossover design. The normally distributed
secondary endpoint, Epworth Sleepiness Scale, hoped to observe negative test statistics. Therefore, we
consider the decrease as the endpoint in order to retain the same hypothesis tests as before H0d : τd ≤
0, H1d : τd > 0, d = 1, 2, 3. The trial planned to recruit 90 patients, and utilising restricted error
maximum likelihood estimation, the final analysis calculated that σ2e = 6.51. Taking this variance as the
truth, the trial had a familywise error rate α = 0.05 for τ = (τ1, τ2, τ3)
T = (0, 0, 0)T, and β = 0.2 for H11
at τ1 = 1.11.
Many methods exist for determining boundaries for a one-sided group sequential trial with parallel
treatment arms. Here, we consider analogues of the power family boundaries of Pampallona and Tsiatis
(1994). For this, values for the desired type-I and type-II error rates, a clinically relevant difference δ,
the maximum number of stages L, the within person variance σ2e , and a shape parameter ∆ must be
specified. A 2-dimensional grid search is then used to find the exact required maximal sample size. From
this a suitable value of n is identified by rounding up to the nearest integer such that n is as required
divisible by |S2|, . . . , |SD|. Utilizing Williams squares for our designs, n was forced to be divisible by 12.
Taking α = 0.05, β = 0.2, δ = 1.11, σ2e = 6.51, L = 3, and ∆ = −0.25, 0, 0.5, 0.5 as examples,
group sequential crossover trial designs were determined and compared to the single-stage design used by
TOMADO. All computations were done in R (R Core Team, 2016) using the package groupSeqCrossover,
available from the corresponding author upon request. Matlab (The Mathworks Inc., 2016) code employ-
ing symbolic algebra is also available to return the matrices given by several of the equations in the text.
Use of both the R and Matlab code is detailed in Appendix D.
A summary of the performance of the designs is provided in Table 1, and their computed boundaries
are displayed in Figure 1. We can see that, as is the case for two-arm parallel trial designs, there is a
trend that larger values of ∆ result in larger maximum sample sizes and lower expected sample sizes due
to their larger stopping regions. However, this is not the case for ∆ = 0.25 because of the requirement
to round to a suitable integer value of n.
Plots of the probability of rejecting H01, and rejecting H0d for some d = 1, 2, 3, are provided for a
range of values of θ when τ = (θ, θ, θ)T in Figure 2. The power curves are similar for all the designs, with
the only differences a result of rounding in the group sequential designs to achieve suitable values of n.
As is to be expected for group sequential designs, the maximum sample size and maximum number of
observations is larger than for the single-stage design. However, the group sequential designs have lower
expected sample sizes under the global null hypothesis (τ = 0 = (0, 0, 0)T); up to a maximum of 23%
for ∆ = 0.5. Though, this comes at the expense of an increased expected sample size under the global
alternative hypothesis (τ = δ = (δ, δ, δ)T).
From Figure 3, the expected sample sizes of the group sequential designs can be seen to be far lower
than the single-stage design for more extreme values of θ. A similar statement holds for the expected
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Table 1: Example Design Performance. Summary of the performance of the single-stage and considered
group sequential designs. The number of decimal places displayed in each row indicates the number to
which rounding was performed
Design
Single-stage ∆ = −0.25 ∆ = 0 ∆ = 0.25 ∆ = 0.5
n 90 36 36 48 48
pr (Reject H01 | τ = 0) 0.02 0.02 0.02 0.02 0.02
pr (Reject H01 | τ = δ) 0.80 0.85 0.83 0.90 0.83
pr (Reject H0d for some d | τ = 0) 0.05 0.05 0.05 0.05 0.05
pr (Reject H0d for some d | τ = δ) 0.95 0.97 0.97 0.98 0.97
E (N | τ = 0) 90.0 76.8 70.0 82.6 69.6
E (N | τ = δ) 90.0 100.3 95.7 110.7 98.9
E (O | τ = 0) 360.0 269.3 240.3 283.1 244.5
E (O | τ = δ) 360.0 367.2 341.8 380.4 327.7
maxN 90 108 108 144 144
maxO 360 432 432 576 576
number of observations. However, in this instance for ∆ = 0, 0.5, the performance of the group sequential
designs is better than the single-stage design across all values of θ.
4. DISCUSSION
There is a long history on group sequential clinical trials. Very few however utilise a crossover design.
This may at least in part be due to no formal proof existing for how to strongly control the familywise
error rate of such a trial. Here, we provided such a proof and then explored the performance of several
sequential designs for the TOMADO trial.
The expected sample size of the sequential designs was observed to be far lower than that of the
single-stage design for a large range of values of the true response rate on all experimental treatments.
Unfortunately, but unsurprisingly given the trial is not stopped unless all experimental treatments are
dropped, there are regions in which the sequential designs are less efficient. Indeed, this region includes
some values of θ between 0 and δ, which may be more realistic observed treatment effects. However, for
some considered designs this region is very small and does not include values near 0, which is notable
for ethical reasons. This issue could even be further alleviated by utilising optimal stopping boundaries,
as has been proposed for parallel arm designs (Wason and Jaki, 2012; Wason et al., 2012). Importantly,
several of the designs always performed better than the single-stage design in terms of the expected
number of observations required, which could be a significant factor in the cost and length of a trial.
Consequently, we can conclude that a group sequential approach to a crossover trial improves efficiency
in some circumstances.
Several possible extensions to our work present themselves. For example, we assumed that period
was reset in each trial stage. This could reflect a scenario where it is believed being enrolled in the trial
will alter a patient’s behaviour. However, in some cases, such as to deal with seasonal effects, it would
12
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Figure 1: Stopping Boundaries. Computed efficacy and futility boundaries of the considered group
sequential designs.
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be preferential to have different period effects in each stage.
One simple extension would be to non-inferiority tests, from our present superiority testing framework.
Non-inferiority tests, seeking to determine if new treatments are not clinically worse than an established
control, would have hypotheses shifted by some factor from the ones presented here. Theorem 2.2 could
easily be altered to accommodate this, and then popular methods for boundary determination in this
setting applied.
Here, we have worked under an idealised scenario, assuming the within patient variance to be known
prior to trial commencement. Though this is a common assumption in group sequential theory, it does
bring limitations, since often a good estimate for the key variance parameter cannot be provided at the
design stage. In this instance group sequential t-tests would almost certainly be required. Furthermore,
simulation is required to quantify error rates accurately in the case of small sample sizes. To explore this
scenario we analysed the true familywise error rate under the global null hypothesis of a particular design
motivated again by the TOMADO trial, but with L = 2 and n = 12. We found that provided restricted
error maximum likelihood was utilised, there was very little inflation in the familywise error rate over the
nominal level α. Details of this are provided in Appendix B.
Moreover, we have only explored designing group sequential crossover trials. It is well known that if a
final analysis is performed on data acquired in a sequential trial, not taking in to account the sequential
nature, then biased treatment effects will be acquired. Extending established methodology for parameter
estimation to our scenario will thus be important.
Finally, we have implicitly assumed that there will be no patient drop out, and have not discussed
the issue of patient recruitment rates. Though these are problems for all adaptive designs it is important
to give them note. Owing to our need for one stages data to be analysed before the commencement
of the following stage, it is likely the length of a trial using our approach would be longer for certain
recruitment rates. It could be that recruitment is paused at interim, or that patients are continually
recruited under the old scheme until results are available, which would lead to overrun and an increase in
the expected number of observations and sample size. Thus this would be an important factor to consider
when choosing an appropriate design for a trial.
Nevertheless, for future crossover trials, consideration should be given to a group sequential approach.
This may assist substantially in the efficient prioritisation of efficacious treatments.
APPENDIX A: FURTHER TECHNICAL DETAILS
As discussed in Section 2, part (1) of Theorem 2.1 implies that
cov(τˆd1l, τˆd2l | Ll1, . . . , LlD−1 = 0, LlD = l) =
σ2e
ln
(1 + δd1d2),
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for d1, d2 ∈ {1, . . . , D− 1}. Alternatively, it tells us that in this case Idl = ln/(2σ2e), for d = 1, . . . , D− 1.
Moreover, using the above along with Equation (2.1), in conjunction with part (2) of Theorem 2.1,
we have that if fp ≤ Zd1p < ep for p = 0, . . . , l1 − 1 (i.e. if treatment d1 is present up to stage l1)
and fq ≤ Zd2q < eq for q = 0, . . . , l2 − 1 (i.e. if treatment d2 is present up to stage l2), with l1 ≤ l2,
l1, l2 ∈ {1, . . . , L} and d1, d2 ∈ {1, . . . , D − 1} (taking f0 = −∞ and e0 =∞) then
Id1a =
an
2σ2e
,
Id2b =
bn
2σ2e
,
cov(Zd1a, Zd2b | ω,ψ) = I1/2d1acov(τˆd1b, τˆd2b | Lb1, . . . , LbD)I
1/2
d2b
=
(
an
2σ2e
)1/2
σ2e
bn
(1 + δd1d2)
(
bn
2σ2e
)1/2
,
=
1
2
(a
b
)1/2
(1 + δd1d2),
for a ≤ b, a = 1, . . . , l1, and b = 1, . . . , l2.
For further clarity, as an example, consider the case D = 3, L = 2, and the associated value of
pr (ωR = ω,ψR = ψ | τ ) when ω = (2, 1)T and ψ = (1, 0)T. Using the above we know the following
elements of the matrix Λ(ω,ψ) and vector I(ω,ψ) = (I
T
1,(ω,ψ), I
T
2,(ω,ψ))
T
Λ(ω,ψ) =

1 12
(
1
2
)1/2 •
1
2 1
1
2
(
1
2
)1/2 •(
1
2
)1/2 1
2
(
1
2
)1/2
1 •
• • • •

,
I(ω,ψ) =
(
n
2σ2e
,
n
2σ2e
,
2n
2σ2e
, •
)T
,
where we have used • to signify an element we do not know the value of.
Now consider our computation of pr (ωR = ω,ψR = ψ | τ ). We have
pr (ωR = ω,ψR = ψ | τ ) =
∫ e1
f1
∫ f1
−∞
∫ ∞
e2
∫ ∞
−∞
φ
{
x, r(τ , 2) ◦ I(ω,ψ),Λ(ω,ψ)
}
dx22dx12dx21dx11.
As we have seen we do not know the values of the final row and column of the matrix Λ(ω,ψ), or the
final element of the vector I(ω,ψ). But, the fact mentioned in Theorem 2.2 becomes clear: this does not
matter as the limits of integration corresponding to this variable are (−∞,∞). Indeed, by the marginal
distribution properties of the multivariate normal distribution, we need only as stated consider one matrix
Λ(ω,ψ), and one set of vectors I l,(ω,ψ); exactly those given by the case ω = (L, . . . , L)
T. We denote these
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by Λ and I l, and set I = (I
T
1 , . . . , I
T
L). Explicitly, we have
cov(Zd1l1 , Zd2l2) = Λd1+(D−1)(l1−1),d2+(D−1)(l2−1),
=
1
2
(
l1
l2
)1/2
(1 + δd1d2),
Idl =
ln
2σ2e
,
for any d, d1, d2 ∈ {1, . . . , D − 1} and l1 ≤ l2, l, l1, l2 ∈ {1, . . . , L}.
APPENDIX B: SMALL SAMPLE SIZE PERFORMANCE
For small sample sizes, simulation is required to accurately determine a designs performance. Since
crossover trials are routinely conducted with small sample sizes, we here explore the impact this has
upon the familywise error rate under the global null hypothesis.
We determined a design corresponding to the TOMADO example that would require only 12 patients
in each of two stages: the smallest allowable maximum sample size for a group sequential crossover trial
with D = 4 treatments initially, given our restrictions on n. Taking ∆ = 0 as an example, a trial with
n = 12 and L = 2 with f1 = 0.768, f2 = 2.036 and e1 = 2.879 to 3 decimal places, would using our
multivariate normal calculations have a maximal familywise error rate of α = 0.05 under the global null
hypothesis, and β = 0.2 for δ = 2.2 when σ2e = 6.51.
Ten-thousand of these trials were simulated in order to ascertain the true probability of rejecting H0d
for some d = 1, 2, 3, when τ = (0, 0, 0)T. For simplicity, pij was set to 0 for j = 2, . . . , D, and µ0 was set
to 0. Incorporating non-zero period effects however would not be expected to greatly effect the results.
Whitehead et al. (2009) proposed a quantile substitution procedure for adapting the boundaries
of a sequential trial to be more suitable to the case of unknown variance. We additionally considered
employing this procedure. Given there is no consensus on how to determine the degrees of freedom when
analysing using linear mixed models, we took the degrees of freedom at any analysis to be the classical
decomposition of degrees of freedom in balanced, multilevel ANOVA designs (Pinheiro and Bates, 2009).
Moreover, we also assessed the performance of the sequential design when the linear mixed model was
fitted through either maximum likelihood or restricted error maximum likelihood estimation. Therefore in
total these simulations were performed for each of four possible analysis procedures: maximum likelihood
or restricted error maximum likelihood estimation, with or without boundary adjustment through quantile
substitution.
Thus, for each simulated study, patient response data for each stage l was randomly generated ac-
cording to the distribution implied by their allocated treatment sequence (assigned according to the rules
of the trial design), using the function rmvnorm (Genz et al., 2016) in R. The between person variance
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Table 2: Performance of the small sample size group sequential crossover trial design under four analysis
procedures (ML = Maximum Likelihood, REML = Restricted Error Maximum Likelihood). Specifically,
pr (Reject H0d for some d | τ = 0) is shown for each procedure to 3 decimal places based on 10000 trial
simulations
Procedure Estimation Boundary Adjustment pr (Reject H0d for some d | τ = 0)
Procedure 1 ML No 0.077
Procedure 2 ML Yes 0.062
Procedure 3 REML No 0.055
Procedure 4 REML Yes 0.051
was set to σ2b = 10.12; the value ascertained in the final analysis of the TOMADO trial data. Follow-
ing this, our linear mixed model was fitted on all accumulated data (with either maximum likelihood
or restricted error maximum likelihood estimation according to the particular analysis procedure being
considered) and Zdl = τˆdlIˆ
1/2
dl determined for d = 1, 2, 3, where Iˆ
1/2
dl is the observed Fisher information
for τˆdl. Then, each Zdl was compared to el and fl and our stopping rules applied (with el and fl ad-
justed using quantile substitution if the analysis procedure under consideration so dictated). If for some
d = 1, 2, 3, fl ≤ Zdl < el, the trial proceeded to the following stage and the process was repeated. In each
instance, simulations in which H0d was rejected for some d = 1, 2, 3 were recorded in order to ascertain
true rejection rates.
The performance of these procedures is displayed in Table 2. We observe that when maximum
likelihood estimation is utilised and the boundaries are not adjusted using the procedure of Whitehead
et al. (2009), there is substantial inflation in the familywise error rate under the global null hypothesis
to 0.077. However, when restricted error maximum likelihood estimation is used, there is only negligible
inflation if adjustment of the boundaries is employed. A program to perform this analysis is available.
Its use is detailed in Appendix D.
APPENDIX C: TECHNICAL PROOFS
Lemma 4.1. Element pq of Σ−1r is given by
Σ−1rpq =
1
σ2e(σ
2
e + rσ
2
b )
{(σ2e + rσ2b )δpq − σ2b}. (4.1)
Proof. We demonstrate this by verifying ΣrpsΣ
−1
rsq = δpq. From the chosen covariance for a patient’s
responses, we have that element pq of Σr is given by
Σrpq = σ
2
bZrpsZ
T
rsq + σ
2
eδpq = σ
2
b + σ
2
eδpq, (4.2)
where Zrpq, (p = 1; q = 1, . . . , r), is the pqth element of Zr; the random effects design matrix for a single
19
individual when there are r treatments remaining. Then
ΣrpsΣ
−1
rsq =
1
σ2e(σ
2
e + rσ
2
b )
r∑
s=1
{
σ2b + σ
2
eδps
}{
(σ2e + rσ
2
b )δsq − σ2b
}
,
=
1
σ2e(σ
2
e + rσ
2
b )
r∑
s=1
{
σ2b (σ
2
e + rσ
2
b )δsq − σ4b + σ2e(σ2e + rσ2b )δpq
−σ2eσ2bδps
}
,
=
1
σ2e(σ
2
e + rσ
2
b )
{
σ2b (σ
2
e + rσ
2
b )− rσ4b + σ2e(σ2e + rσ2b )δpq − σ2eσ2b
}
,
= δpq,
using
∑
s δsq =
∑
s δps = 1.
Lemma 4.2. Take the vector of fixed effects β to be
β = (µ0, pi2, . . . , piD, τ2, . . . , τD−1)T.
Then we have the following result
|Sr|∑
i=1
n
|Sr|
X
T
sri
Σ
−1
r Xsri
= n

A BT 01,D−r BT 01,D−r
B C 0r−1,D−r E 0r−1,D−r
0D−r,1 0D−r,r−1 0D−r,D−r 0D−r,r−1 0D−r,D−r
B E 0r−1,D−r C 0r−1,D−r
0D−r,1 0D−r,r−1 0D−r,D−r 0D−r,r−1 0D−r,D−r

, (4.3)
where 0m,n is a matrix of zeroes of dimension m× n, and
A =
rσ2e
σ2e(σ2e + rσ
2
b )
,
Bpq =
rσ2e
σ2e(σ2e + rσ
2
b )
(p = 1, . . . , r − 1; q = 1),
Cpq =
1
σ2e(σ2e + rσ
2
b )
{(σ2e + rσ2b )δpq − σ2b} (p = 1, . . . , r − 1; q = 1, . . . , r − 1),
Epq =
1
r
σ2e
σ2e(σ2e + rσ
2
b )
(p = 1, . . . , r − 1; q = 1, . . . , r − 1).
Proof. Denote the columns of Xsri by
Xsri =
(
1r Π2r . . . ΠDr T 1sri . . . TD−1sri
)
.
Thus Πjr is the column corresponding to the period effect pij , T dsri to the treatment effect τd, and 1r
to the intercept µ0. Using this representation, and Lemma 4.1, we have
20
XTsriΣ
−1
r Xsri =

1Tr
ΠT2r
...
TTD−1sri

Σ−1r
(
1r Π2r . . . TD−1sri
)
=

1TrΣ
−1
r 1r 1
T
rΣ
−1
r Π2r . . . 1
T
rΣ
−1
r TD−1sri
ΠT2rΣ
−1
r 1r Π
T
2rΣ
−1
r Π2r . . . Π
T
2rΣ
−1
r TD−1sri
...
...
. . .
...
TTD−1sriΣ
−1
r 1r T
T
D−1sriΣ
−1
r Π2r . . . T
T
D−1sriΣ
−1
r TD−1sri

.
Here, dim(Πjr) = dim(1r) = dim(T jsri) = r × 1, for all i and j. Therefore 1TrΣ−1r 1r, ΠTjrΣ−1r 1r,
T TjsriΣ
−1
r 1r, 1
T
rΣ
−1
r Πjr, 1
T
rΣ
−1
r T jsri , Π
T
jrΣ
−1
r Πkr, T
T
jsriΣ
−1
r T ksri and Π
T
jrΣ
−1
r T ksri are scalars for all
i, j and k.
By the definition of being in period j, the vth element of Πjr is given by
Πjrv = δjv.
Whilst, since complete block design sequences are used, the vth element of T jsri is given by
T jsriv = δ1Ijsriv ,
where
Ijsriv =
 1 An individual on sequence sri receives treatment j in period v,0 otherwise.
We denote this non-zero element, if it exists, by tj .
Now from the symmetry present in Σ−1r , using Lemma 4.1 we have
∑
j,k
Σ−1rjk =
rσ2e
σ2e(σ
2
e + rσ
2
b )
,
and ∑
j
Σ−1rjk =
∑
k
Σ−1rjk =
σ2e
σ2e(σ
2
e + rσ
2
b )
,
for all j and k. Therefore, we can determine the form of each of the scalar elements in the matrix above
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as follows
1TrΣ
−1
r 1r =
∑
j,k
Σ−1rjk =
rσ2e
σ2e(σ
2
e + rσ
2
b )
,
ΠTjrΣ
−1
r 1r = 1
T
rΣ
−1
r Πjr =
∑
k
Σ−1rjkI{j≤r} =
σ2e
σ2e(σ
2
e + rσ
2
b )
I{j≤r},
TTjsriΣ
−1
r 1r = 1
T
rΣ
−1
r T jsri =
∑
k
Σ−1rtjkI{j≤r−1} =
σ2e
σ2e(σ
2
e + rσ
2
b )
I{j≤r−1},
ΠTjrΣ
−1
r Πkr = Σ
−1
rjkI{j≤r}I{k≤r} =
{
(σ2e + rσ
2
b )I{j=k} − σ2b
σ2e(σ
2
e + rσ
2
b )
}
I{j≤r}I{k≤r},
TTjsriΣ
−1
r T ksri = Σ
−1
rtjtk
I{j≤r−1}I{k≤r−1} =
{
(σ2e + rσ
2
b )I{j=k} − σ2b
σ2e(σ
2
e + rσ
2
b )
}
I{j≤r−1}I{k≤r−1},
ΠTjrΣ
−1
r T ksri = Σ
−1
rjtk
I{j≤r}I{k≤r−1} =
{
(σ2e + rσ
2
b )I{j=tk} − σ2b
σ2e(σ
2
e + rσ
2
b )
}
I{j≤r}I{k≤r−1}.
As a final step we must compute the sum across sequences, i.e. over the index i. We can see instantly
that we have confirmed the elements proposed to be 0 in
∑|Sr|
i=1 nX
T
sriΣ
−1
r Xsri/ |Sr| are indeed so, and
we therefore need only concentrate on the non-zero terms suggested; A, B, C and E.
However, other than ΠTjrΣ
−1
r T ksri , all the elements above have been identified as independent of
sequence sri. Therefore computing the sum over the sri ∈ Sr can be done easily, and gives the forms
proposed for A, B and C in the statement of the Lemma immediately, on multiplying through by
n/ |Sr|. But, by our imposed constraint that sequences be balanced for period we can also sum over
the ΠTjrΣ
−1
r T ksri
|Sr|∑
i=1
n
|Sr|
ΠTjrΣ
−1
r Tksri =
n
|Sr|
(
|Sr|
r
[
1
σ2e(σ
2
e + rσ
2
b )
{
σ2e + (r − 1)σ2b
}]
+
{
1− |Sr|
r
}{ −σ2b
σ2e(σ
2
e + rσ
2
b )
})
,
=
n
|Sr|
{
|Sr|
r
σ2e
σ2e(σ
2
e + rσ
2
b )
}
,
= n
1
r
σ2e
σ2e(σ
2
e + rσ
2
b )
,
since exactly |Sr| /r patients receive each treatment at each time period. This confirms the form proposed
for E, and the proof is complete.
Theorem 4.3. (Theorem 2.1 from Section 2) Let β = (µ0, pi2, . . . , piD, τ1, . . . , τD−1)T. Consider an
analysis to be performed after some number of stages l. Then
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1. We have
cov(βˆl, βˆl | Ll1, . . . , LlD−1 = 0, LlD = l) =
 ln
|SD|
|SD|∑
i=1
XTsDiΣ
−1
D XsDi
−1 ,
=
1
ln

F GT GT
G H 0D−1,D−1
G 0D−1,D−1 H
 , (4.4)
where
F = σ2b +
2D − 1
D
σ2e ,
Gpq = −σ2e (p = 1, . . . , D − 1; q = 1),
Hpq = σ
2
e(1 + δpq) (p = 1, . . . , D − 1; q = 1, . . . , D − 1).
2. If q ≥ 2 is the largest integer such that Llr = 0 for r = 1, . . . , q − 1, then the covariance of the
estimates of the fixed effects pˆi2l, . . . , pˆiql, τˆ1l, . . . , τˆq−1l is identical to that it would be for Ll1 =
· · · = LlD−1 = 0. Moreover, the covariance between the estimates of pˆi2l, . . . , pˆiql, τˆ1l, . . . , τˆq−1l and
the estimates of pˆiq+1l, . . . , pˆiDl, τˆql, . . . , τˆD−1l is also identical to that it would be for Ll1 = · · · =
LlD−1 = 0.
Proof. 1. We begin with the result for the case Ll1 = · · · = L1D−1 = 0. We demonstrate this by
confirming
cov(βˆl, βˆl | Ll1, . . . , LlD−1 = 0, LlD = l)−1cov(βˆl, βˆl | Ll1, . . . , LlD−1 = 0, LlD = l) = I2D−1.
By Lemma 4.2 we know that
cov(βˆl, βˆl | Ll1, . . . , LlD−1 = 0, LlD = l)−1 = ln

A BT BT
B C E
B E C
 ,
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for
A =
Dσ2e
σ2e(σ
2
e +Dσ
2
b )
,
B =
Dσ2e
σ2e(σ
2
e +Dσ
2
b )

1
...
1
 ,
C =
1
σ2e(σ
2
e +Dσ
2
b )

σ2e + (D − 1)σ2b −σ2b . . . −σ2b
−σ2b σ2e + (D − 1)σ2b
. . .
...
...
. . .
. . . −σ2b
−σ2b . . . −σ2b σ2e + (D − 1)σ2b

,
E =
1
D
σ2e
σ2e(σ
2
e +Dσ
2
b )

1 . . . 1
...
. . .
...
1 . . . 1
 ,
with
dim(B) = (D − 1)× 1,
dim(C) = (D − 1)× (D − 1),
dim(E) = (D − 1)× (D − 1).
Thus we must show 
A BT BT
B C E
B E C


F GT GT
G H 0D−1,D−1
G 0D−1,D−1 H
 = I2D−1,
or on expanding
AF + 2BTG = 1,
BGT +CH = ID−1,
BGT +EH = 0D−1,D−1,
BF +CG+EG = 0D−1,1,
AGT +BTH = 01,D−1.
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Now
AF + 2B
T
G =
 Dσ2e
σ2e(σ
2
e +Dσ
2
b
)
(σ2b + 2D − 1
D
σ
2
e
)
+ 2
σ2e
σ2e(σ
2
e +Dσ
2
b
)

1
.
.
.
1

T
(−σ2e)

1
.
.
.
1

,
=
 Dσ2e
σ2e(σ
2
e +Dσ
2
b
)
(σ2b + 2D − 1
D
σ
2
e
)
− 2(D − 1)σ2e
σ2e
σ2e(σ
2
e +Dσ
2
b
)
,
= 1,
BG
T
+ CH =
σ2e
σ2e(σ
2
e +Dσ
2
b
)

1
.
.
.
1

(−σ2e)

1
.
.
.
1

T
+
1
σ2e(σ
2
e +Dσ
2
b
)

σ2e + (D − 1)σ2b −σ
2
b . . . −σ
2
b
−σ2b σ
2
e + (D − 1)σ2b
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. −σ2b
−σ2b . . . −σ
2
b σ
2
e + (D − 1)σ2b

×
× (σ2e)

2 1 . . . 1
1
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. 1
1 . . . 1 2

,
= −
σ4e
σ2e(σ
2
e +Dσ
2
b
)

1 1 . . . 1
1
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. 1
1 . . . 1 1

+
σ2e
σ2e(σ
2
e +Dσ
2
b
)

2σ2e σ
2
e . . . σ
2
e
σ2e 2σ
2
e
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. σ2e
σ2e . . . σ
2
e 2σ
2
e

,
= ID−1,
BG
T
+ EH =
σ2e
σ2e(σ
2
e +Dσ
2
b
)

1
.
.
.
1

(−σ2e)

1
.
.
.
1

T
+
1
D
σ2e
σ2e(σ
2
e +Dσ
2
b
)

1 1 . . . 1
1
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. 1
1 . . . 1 1

(σ
2
e)

2 1 . . . 1
1
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. 1
1 . . . 1 2

,
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= −
σ4e
σ2e(σ
2
e +Dσ
2
b
)

1 1 . . . 1
1
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. 1
1 . . . 1 1

+
1
D
σ4e
σ2e(σ
2
e +Dσ
2
b
)

D D . . . D
D
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. D
D
.
.
. D D

,
= 0D−1,D−1,
BF + CG + EG =
σ2e
σ2e(σ
2
e +Dσ
2
b
)

1
1
.
.
.
1

(
σ
2
b +
2D − 1
D
σ
2
e
)
+
1
σ2e(σ
2
e +Dσ
2
b
)

σ2e + (D − 1)σ2b −σ
2
b . . . −σ
2
b
−σ2b σ
2
e + (D − 1)σ2b
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. −σ2b
−σ2b . . . −σ
2
b σ
2
e + (D − 1)σ2b

×
× (σ2e)

1
1
.
.
.
1

+
1
D
σ2e
σ2e(σ
2
e +Dσ
2
b
)

1 1 . . . 1
1
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. 1
1 . . . 1 1

(−σ2e)

1
1
.
.
.
1

,
=
σ2e
σ2e(σ
2
e +Dσ
2
b
)
(
σ
2
b +
2D − 1
D
σ
2
e
)

1
1
.
.
.
1

−
σ2e
σ2e(σ
2
e +Dσ
2
b
)
(σ
2
e + σ
2
b )

1
1
.
.
.
1

−
1
D
σ4e
σ2e(σ
2
e +Dσ
2
b
)
(D − 1)

1
1
.
.
.
1

,
= 0D−1,1,
AG
T
+B
T
H =
 Dσ
2
e
σ2e(σ
2
e +Dσ
2
b
)
 (−σ2e)

1
1
.
.
.
1

T
+
 σ
2
e
σ2e(σ
2
e +Dσ
2
b
)


1
1
.
.
.
1

T
(σ
2
e)

2 1 . . . 1
1
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. 1
1 . . . 1 2

,
= −
Dσ4e
σ2e(σ
2
e +Dσ
2
b
)

1
1
.
.
.
1

T
+
σ4e
σ2e(σ
2
e +Dσ
2
b
)
D

1
1
.
.
.
1

T
,
= 01,D−1,
as required. Thus, the proposed matrix is indeed cov(βˆl, βˆl | Ll1, . . . , LlD−1 = 0, LlD = l).
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2. For the next part of the theorem, we re-order our vector of fixed effects such that
β = (µ0, pi2, τ1, pi3, τ2, . . . , piD, τD−1)T,
and thus the ordering of the columns of the Xsri is now
Xsri =
(
1r Π2r T 1sri Π3r T 2sri . . . ΠDr TD−1sri
)
.
We proceed by induction over the number of stages completed l, for general D. Now, we assume that
at the lth interim analysis, the statement of the Theorem is true. Now, the covariance at this lth analysis
is
cov(βˆl, βˆl | Ll1 = · · · = Llq−1 = 0, Llq , . . . , LlD) =
 D∑
r=q
Lr
n
|Sr|
|Sr|∑
i=1
XTsriΣ
−1
r Xsri
−1
= A−1.
It is this specifically we assume follows the required condition. Additionally, we assume that this
covariance matrix can be computed, i.e. that A is invertible. We show that if we conduct another stage
of the trial with t treatments remaining, 2 ≤ t ≤ q, then the new covariance matrix
cov(βˆl+1, βˆl+1 | Ll+11, . . . , Ll+1D) =
A+ n|St|
|St|∑
i=1
XTstiΣ
−1
t Xsti
−1
= (A+B)
−1
,
has the required property for pˆi2l, . . . , pˆitl, τˆ1l, . . . , τˆt−1l as well as for pˆi2l, . . . , pˆitl, τˆ1l, . . . , τˆt−1l and
pˆit+1l, . . . , pˆiDl, τˆtl, . . . , τˆD−1l. Let
T l = (µˆ0l, pˆi2l, τˆ1l, . . . , pˆitl, τˆt−1l)T,
T ′l = (pˆit+1l, τˆtl, . . . , pˆiDl, τˆD−1l)
T,
W l = (pˆi2l, τˆ1l, . . . , pˆitl, τˆt−1l)T.
Denote dim(T l) = |Tl|, and similarly for T ′l and W l.
By our assumptions, we can write
A−1 =
A−1T lT l A−1T lT ′l
A−1T ′lT l A
−1
T ′lT
′
l
 ,
where for example A−1T lT l = cov(T l,T l | Ll1, . . . , LlD), and with A−1TlTl and A−1T ′lT l = (A
−1
T lT ′l
)T holding
the required conditions for the fixed effects. Finally, as part of our inductive hypothesis we also assume
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that det(A−1T lT l) > 0.
With these definitions, our aim can then be stated to prove that
cov(W l+1,W l+1 | Ll+11, . . . , Ll+1D) = l
l + 1
A−1W lW l ,
i.e. that the covariance between the fixed effects pˆi2l, . . . , pˆitl and τˆ1l, . . . , τˆt−1l is l/(l+ 1) that of its form
at interim analysis l, and similarly that
cov(W ′l+1,W l+1 | Ll+11, . . . , Ll+1D) =
l
l + 1
A−1W ′lW l .
For brevity, from here we will write
cov(βˆl, βˆl | Ll1, . . . , LlD) = cov(βˆl, βˆl),
and similarly for T l, T
′
l and W l, for any l.
We use the following identity, which requires only the invertibility of A to be valid (Henderson and
Searle, 1981)
(A+UCV )−1 = A−1
{
I −UCV A−1(I +UCV A−1)−1} .
Note that we can write
B =
BT l+1T l+1 0
0 0
 =
I |T l+1|
0
BT l+1T l+1 (I |T l+1| 0) = UCV ,
since our general form for
∑|St|
i=1X
T
stiΣ
−1
t Xsti is only non-zero in a |T l| × |T l| block in the top left hand
corner by Lemma 4.2. Therefore, provided A is invertible, we can always invert A + B to find the
covariance matrix at the following interim analysis. Moreover, we have
BA−1 =
BT l+1T l+1 0
0 0

A−1T lT l A−1T lT ′l
A−1T ′lT l A
−1
T ′lT
′
l
 ,
=
BT l+1T l+1A−1T lT l BT l+1T l+1A−1T lT ′l
0 0
 ,
and
I2D−1 +BA−1 =
BT l+1T l+1A−1T lT l + I |T l| BT l+1T l+1A−1T lT ′l
0 I |T ′l|
 ,
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Now we need the formula (Henderson and Searle, 1981)
M =
E F
G H
 ,
⇒M−1 =
 (E − FH−1G)−1 −E−1F (H −GE−1F )−1
−H−1G(E − FH−1G)−1 (H −GE−1F )−1
 ,
which implies
(I2D−1 +BA−1)−1 =
(BT l+1T l+1A
−1
T lT l
+ I|T l|)
−1 −(BT l+1T l+1A
−1
T lT l
+ I|T l|)
−1BT l+1T l+1A
−1
T lT
′
l
0 I|T ′
l
|
 .
Note that to use this block matrix inversion formula we require BT l+1T l+1A
−1
T lT l
+I |T l| to be invertible.
However, by the previous result of this theorem only the variance of the intercept term in the form for
A−1T lT l is dependent upon the value of t, so we have that
BT l+1T l+1A
−1
T lT l
=
1
l
 V1 0
V 2 I |T l|−1
 = 1
l
 V1 0
V 2 I |W l|
 ,
for some V1,V 2; dim(V1) = 1× 1,dim(V 2) = |W l| × 1. Now, by Lemma 4.4 det(B−1T l+1T l+1) > 0, which
gives det(BT l+1T l+1) = {det(B−1T l+1T l+1)}−1 > 0. By assumption det(A−1T lT l) > 0, and thus
det(BT l+1T l+1A
−1
T lT l
) = det(BT l+1T l+1)det(A
−1
T lT l
) =
(
1
l
)|W l|
V1 > 0,
⇒ V1 > 0.
Therefore
BT l+1T l+1A
−1
T lT l
+ I |T l| =
1
l
V1 + l 0
V 2 (1 + l)I |W l|
 ,
⇒ det(BT l+1T l+1A−1T lT l + I |T l|) > 0,
and BT l+1T l+1A
−1
T lT l
+ I |T l| is therefore invertible as required.
Now
cov(βˆl+1, βˆl+1) =

A
−1
T lT l
A
−1
T lT
′
l
A
−1
T ′
l
T l
A
−1
T ′
l
T ′
l
×
×
I2D−1 −
BT l+1T l+1A
−1
T lT l
BT l+1T l+1
A
−1
T lT
′
l
0 0

(BT l+1T l+1A
−1
T lT l
+ I|T l|)
−1 −(BT l+1T l+1A
−1
T lT l
+ I|T l|)
−1BT l+1T l+1A
−1
T lT
′
l
0 I|T ′
l
|

 .
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We thus have
cov(T l+1,T l+1) = A
−1
T lT l
{
I |T l| −BT l+1T l+1A−1T lT l(BT l+1T l+1A
−1
T lT l
+ I |T l|)
−1} ,
= A−1T lT l
[
I |T l| −
{
I |T l| + (BT l+1T l+1A
−1
T lT l
)−1
}−1]
,
cov(T ′l+1,T l+1) = A
−1
T ′
l
T l
{
I |T l| −BT l+1T l+1A−1T lT l(BT l+1T l+1A
−1
T lT l
+ I |T l|)
−1} ,
= A−1T ′
l
T l
[
I |T l| −
{
I |T l| + (BT l+1T l+1A
−1
T lT l
)−1
}−1]
,
by the identity DC−1(DC−1 + I)−1 = (I + (DC−1)−1)−1 (Henderson and Searle, 1981), which we can
use as BT l+1T l+1A
−1
T lT l
+ I |T l| is invertible from earlier. Then
cov(T l+1,T l+1) = A
−1
T lT l
I|T l| −
I|T l| −

1
l
V1 0
V 2 I|W l|


−1
−1 ,
= A
−1
T lT l
I|T l| −
I|T l| − l
V1 0
V 2 I|W l|

−1
−1 ,
= A
−1
T lT l
I|T l| −
I|T l| − l
 V
−1
1 0
−I|W l|V 2V
−1
1 I
−1
|W l|


−1 ,
= A
−1
T lT l
I|T l| −
 1 + lV
−1
1 0
−I|W l|V 2V
−1
1 (1 + l)I
−1
|W l|

−1 ,
= A
−1
T lT l
×
×
I|T l| −
 (1 + lV−11 )−1 0
−(1 + l)−1I|W l| × −I|W l|V 2V
−1
1 (1 + lV
−1
1 )
−1 (1 + l)−1I|W l|

 ,
= A
−1
T lT l
I|T l| −
 (1 + lV−11 )−1 0
(1 + l)−1I|W l|V 2V
−1
1 (1 + lV
−1
1 )
−1 (1 + l)−1I|W l|

 ,
= A
−1
T lT l
 1 − (1 + lV−11 )−1 0
(1 + l)−1I|W l|V 2V
−1
1 (1 + lV
−1
1 )
−1 I|W l|(1 + l)
−1I|W l|
 .
Now
det{cov(T l+1,T l+1 | Ll+11, . . . , Ll+1D)} = det(A−1T lT l)det{1− (1 + lV
−1
1 )
−1}
× det{I |W l|−(1+l)−1I|W l|}
> 0,
thus det(A−1T l+1T l+1) > 0 as required, and
cov(W l+1,W l+1) = A
−1
W lW l
{I |W l| − (1 + l)−1I |W l|},
= A−1W lW l
{
l
l + 1
I |W l|
}
,
=
l
l + 1
A−1W lW l .
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Similarly
cov(W ′l+1,W l+1) = A
−1
W ′lW l
{I |W l| − (1 + l)−1I |W l|},
= A−1W ′lW l
{
l
l + 1
I |W l|
}
,
=
l
l + 1
A−1W ′lW l .
Thus the covariance of the fixed effects at the (l + 1)th analysis has the desired property.
Now, as the base case consider having completed one stage of the trial, and proceeding to complete
another with any number of treatments t = 2, . . . , D remaining. Then, in this instance
A =
n
|SD|
|SD|∑
i=1
XTsDiΣ
−1
D XsDi .
By the previous result of this theorem this is indeed invertible and has the desired property, and moreover
by Lemma 4.4 det(A−1T lT l) > 0. The proof is then complete.
Lemma 4.4. Consider the matrix from part (1) of Theorem 4.3; the case Ll1 = · · · = LlD−1 = 0, Lld = l
 ln
|SD|
|SD|∑
i=1
XTsDiΣ
−1
D XsDi
−1 .
Now consider restricting to the columns and rows corresponding to
T l = (µˆ0l, pˆi2l, pˆi3l, . . . , pˆitl, τˆ1l, τˆ2l, . . . , τˆt−1l)T,
for some t = 2, . . . , D. The determinant of this matrix, cov(T l,T l | Ll1 = · · · = LlD−1 = 0, LlD = l), is
strictly positive for any t.
Proof. We have, by part (1) of Theorem 4.3
cov(T l,T l | Ll1 = · · · = LlD−1 = 0, LlD = l) = 1
ln
σ2b + 2D−1D σ2e MT
M N
 ,
31
for
M =

−σ2e
...
−σ2e
 ,
N = σ2e
P 0
0 P
 ,
P =

2 1 . . . 1
1
. . .
. . .
...
...
. . .
. . . 1
1 . . . 1 2

,
dim(M) = (2t− 2)× 1,
dim(N) = 2(t− 1)× 2(t− 1),
dim(P ) = (t− 1)× (t− 1).
Then
det
 1ln
σ2b + 2D−1D σ2e MT
M N

 =
(
1
ln
)2t−1
det

σ2b + 2D−1D σ2e MT
M N

 ,
=
(
1
ln
)2t−1
det(N)det
{(
σ
2
b +
2D − 1
D
σ
2
e
)
−MTN−1M
}
.
Now
N−1 =
1
σ2e
P−1 0
0 P−1
 ,
det(N) = σ4(t−1)e det(P )
2.
We are left therefore to find P−1. We have PQ = ID−1 for
Q =
1
t

t− 1 −1 . . . −1
−1 . . . . . . ...
...
. . .
. . . −1
−1 . . . −1 t− 1

.
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Thus P−1 = Q, and
det

1
ln
σ2b + 2D−1D σ2e MT
M N

 =
( 1
ln
)2t−1
det

σ2b + 2D−1D σ2e MT
M N

 ,
=
( 1
ln
)2t−1
det(N)det
{(
σ
2
b +
2D − 1
D
σ
2
e
)
−MTN−1M
}
,
=
( 1
ln
)2t−1
σ
4(t−1)
e det(P )
2
× det

(
σ
2
b +
2D − 1
D
σ
2
e
)
− σ2e

−1
.
.
.
−1

T Q 0
0 Q


−1
.
.
.
−1


.
This will be strictly positive provided
det

(
σ2b +
2D − 1
D
σ2e
)
− σ2e

−1
...
−1

TQ 0
0 Q


−1
...
−1


> 0.
But
det

(
σ
2
b +
2D − 1
D
σ
2
e
)
− σ2e

−1
.
.
.
−1

T Q 0
0 Q


−1
.
.
.
−1


= det

(
σ
2
b +
2D − 1
D
σ
2
e
)
− σ2e

−1/t
.
.
.
−1/t

T 
−1
.
.
.
−1


,
= det
{(
σ
2
b +
2D − 1
D
σ
2
e
)
− σ2e
(
2t − 2
t
)}
,
= σ
2
b + σ
2
e
( 2
t
−
1
D
)
> 0,
since t ≤ D. Thus, we have the required result.
APPENDIX D: PROGRAMMES
4.1. R
The R package groupSeqCrossover allows the determination, and exploration of, group sequential power
family crossover trial designs. The function gsco is used to determine the design, taking inputs for the
value of L, α, β, δ, σ2e , ∆ and sequence type ("latin" or "williams"). The function plot can then
be used through S3 methods to plot power curves, the expected sample size, and the expected number
of observations, for varying true treatment effects. Moreover, the function simulategsco can be used
to simulate group sequential crossover trials in order to assess their operating characteristics. This is
especially useful in the case of small sample size designs. The code below for example identifies the
discussed design for ∆ = 0 and then plots the expected sample size curve
# Identify the design
Delta.0 <- gsco(Delta = 0)
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# Plot E(N | tau_1 = ... = tau_(D-1) = theta)
plot(Delta.0)
Similarly, the following code would allow the determination of the familywise error rate under the
global null hypothesis (when analysing using maximum likelihood estimation and using quantile substi-
tution on the identified boundaries) of the design discussed in Appendix B
simulate.fwer <- simulategsco(REML = F, adjust = T)
4.2. Matlab
In order to ease the understanding of the forms of Equations (4.1) through (4.4), Matlab code employing
symbolic algebra to return their forms is available. The user details a value for D, and four matrices are
then returned. For example, consider the case D = 4
>> [eq4_1, eq4_2, eq4_3, eq4_4] = groupSeqCrossoverMatrices(4);
eq4 2 contains the Σr for r = 2, 3, 4. Specifically
>> eq4_2
eq4_2 = [ b^2 + e^2, b^2, b^2, b^2]
[ b^2, b^2 + e^2, b^2, b^2]
[ b^2, b^2, b^2 + e^2, b^2]
[ b^2, b^2, b^2, b^2 + e^2]
[ b^2 + e^2, b^2, b^2, 0]
[ b^2, b^2 + e^2, b^2, 0]
[ b^2, b^2, b^2 + e^2, 0]
[ 0, 0, 0, 0]
[ b^2 + e^2, b^2, 0, 0]
[ b^2, b^2 + e^2, 0, 0]
[ 0, 0, 0, 0]
[ 0, 0, 0, 0]
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From this we observe
Σ2 =
σ2e + σ2b σ2b
σ2b σ
2
e + σ
2
b
 ,
Σ3 =

σ2e + σ
2
b σ
2
b σ
2
b
σ2b σ
2
e + σ
2
b σ
2
b
σ2b σ
2
b σ
2
e + σ
2
b
 ,
Σ4 =

σ2e + σ
2
b σ
2
b σ
2
b σ
2
b
σ2b σ
2
e + σ
2
b σ
2
b σ
2
b
σ2b σ
2
b σ
2
e + σ
2
b σ
2
b
σ2b σ
2
b σ
2
b σ
2
e + σ
2
b

.
Note that we have to remove the rows and columns of zeroes from the Σr for r < D, and we use b and e
for σb and σe respectively.
Similarly, eq4 1 contains the forms for Σ−1r for r = 2, 3, 4.
eq4 3 and eq4 4 correspond to the case β = (µ0, pi2, . . . , piD, τ1, . . . , τD−1)T. eq4 3 contains
|Sr|∑
i=1
n
|Sr|X
T
sriΣ
−1
r Xsri (r = 2, 3, 4).
Precisely, the first 2D − 1 rows correspond to the case r = 4, the next 2D − 1 to r = 3, and so forth.
Finally, eq4 4 contains the matrix cov(βˆl, βˆl | ω = (L, . . . , L)T,ψ).
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